147 related articles for article (PubMed ID: 36366390)
1. Adjuvant Treatment for Breast Cancer Patients Using Individualized Neoantigen Peptide Vaccination-A Retrospective Observation.
Zelba H; McQueeney A; Rabsteyn A; Bartsch O; Kyzirakos C; Kayser S; Harter J; Latzer P; Hadaschik D; Battke F; Hartkopf AD; Biskup S
Vaccines (Basel); 2022 Nov; 10(11):. PubMed ID: 36366390
[TBL] [Abstract][Full Text] [Related]
2. Case Report: Targeting of individual somatic tumor mutations by multipeptide vaccination tailored for HLA class I and II presentation induces strong CD4 and CD8 T-cell responses in a patient with metastatic castration sensitive prostate cancer.
Zelba H; Rabsteyn A; Bartsch O; Kyzirakos C; Kayser S; Seibold M; Harter J; Latzer P; Hadaschik D; Battke F; Golf A; Rettig MB; Biskup S
Front Immunol; 2023; 14():1271449. PubMed ID: 37920460
[TBL] [Abstract][Full Text] [Related]
3. Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion.
Cai Z; Su X; Qiu L; Li Z; Li X; Dong X; Wei F; Zhou Y; Luo L; Chen G; Chen H; Wang Y; Zeng Y; Liu X
Mol Cancer; 2021 Dec; 20(1):164. PubMed ID: 34903219
[TBL] [Abstract][Full Text] [Related]
4. Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
Morisaki T; Hikichi T; Onishi H; Morisaki T; Kubo M; Hirano T; Yoshimura S; Kiyotani K; Nakamura Y
Immunol Invest; 2021 Jul; 50(5):562-579. PubMed ID: 32660279
[TBL] [Abstract][Full Text] [Related]
5. Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report.
Sonntag K; Hashimoto H; Eyrich M; Menzel M; Schubach M; Döcker D; Battke F; Courage C; Lambertz H; Handgretinger R; Biskup S; Schilbach K
J Transl Med; 2018 Feb; 16(1):23. PubMed ID: 29409514
[TBL] [Abstract][Full Text] [Related]
6. Case Report: Long-Term Survival of a Patient with Cerebral Metastasized Ovarian Carcinoma Treated with a Personalized Peptide Vaccine and Anti-PD-1 Therapy.
Zelba H; Kyzirakos C; Kayser S; Shao B; Reinhardt A; Pieper N; Rabsteyn A; Döcker D; Armeanu-Ebinger S; Kloor M; Hadaschik D; Schulze M; Battke F; Golf A; Biskup S
Vaccines (Basel); 2024 Apr; 12(4):. PubMed ID: 38675779
[TBL] [Abstract][Full Text] [Related]
7. Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy.
Shou J; Mo F; Zhang S; Lu L; Han N; Liu L; Qiu M; Li H; Han W; Ma D; Guo X; Guo Q; Huang Q; Zhang X; Ye S; Pan H; Chen S; Fang Y
Front Immunol; 2022; 13():1000681. PubMed ID: 36248865
[TBL] [Abstract][Full Text] [Related]
8. A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.
Chen Z; Zhang S; Han N; Jiang J; Xu Y; Ma D; Lu L; Guo X; Qiu M; Huang Q; Wang H; Mo F; Chen S; Yang L
Front Immunol; 2021; 12():691605. PubMed ID: 34484187
[TBL] [Abstract][Full Text] [Related]
9. Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma.
Mørk SK; Kadivar M; Bol KF; Draghi A; Westergaard MCW; Skadborg SK; Overgaard N; Sørensen AB; Rasmussen IS; Andreasen LV; Yde CW; Trolle T; Garde C; Friis-Nielsen J; Nørgaard N; Christensen D; Kringelum JV; Donia M; Hadrup SR; Svane IM
Oncoimmunology; 2022; 11(1):2023255. PubMed ID: 35036074
[TBL] [Abstract][Full Text] [Related]
10. Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High-Risk Gastric/Gastroesophageal Junction Cancer.
Liu Q; Chu Y; Shao J; Qian H; Yang J; Sha H; Cen L; Tian M; Xu Q; Chen F; Yang Y; Wang W; Wang K; Yu L; Wei J; Liu B
Adv Sci (Weinh); 2022 Nov; 10(1):e2203298. PubMed ID: 36351249
[TBL] [Abstract][Full Text] [Related]
11. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4
Hernandez R; LaPorte KM; Hsiung S; Santos Savio A; Malek TR
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34475132
[TBL] [Abstract][Full Text] [Related]
12. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
[TBL] [Abstract][Full Text] [Related]
13. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.
Chen X; Yang J; Wang L; Liu B
Theranostics; 2020; 10(13):6011-6023. PubMed ID: 32483434
[TBL] [Abstract][Full Text] [Related]
14. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
[TBL] [Abstract][Full Text] [Related]
15. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
Aldous AR; Dong JZ
Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
[TBL] [Abstract][Full Text] [Related]
16. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
17. Broadening CD4
Filskov J; Mikkelsen M; Hansen PR; Christensen JP; Thomsen AR; Andersen P; Bukh J; Agger EM
J Virol; 2017 Jul; 91(14):. PubMed ID: 28446674
[TBL] [Abstract][Full Text] [Related]
18. Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines.
Roesler AS; Anderson KS
Methods Mol Biol; 2022; 2410():649-670. PubMed ID: 34914074
[TBL] [Abstract][Full Text] [Related]
19. Neoantigen Landscape Supports Feasibility of Personalized Cancer Vaccine for Follicular Lymphoma.
Ramirez CA; Becker-Hapak M; Singhal K; Russler-Germain DA; Frenkel F; Barnell EK; McClain E; Desai S; Schappe T; Onyeador OC; Kudryashova O; Belousov V; Bagaev A; Ocheredko E; Kiwala S; Hundal J; Skidmore ZL; Watkins MP; Mooney TB; Walker J; Krysiak K; Gomez F; Fronick CC; Fulton RS; Schreiber RD; Mehta-Shah N; Cashen AF; Kahl BS; Ataullakhanov R; Bartlett NL; Griffith M; Griffith OL; Fehniger TA
Blood Adv; 2024 May; ():. PubMed ID: 38713894
[TBL] [Abstract][Full Text] [Related]
20. Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients.
Takahashi R; Toh U; Iwakuma N; Takenaka M; Otsuka H; Furukawa M; Fujii T; Seki N; Kawahara A; Kage M; Matsueda S; Akagi Y; Yamada A; Itoh K; Sasada T
Breast Cancer Res; 2014 Jul; 16(4):R70. PubMed ID: 24992895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
